Cargando…
Promiscuous Ligands
Computational and experimental high-throughput screening are frequently used to discover new leads for drug design. Although novel ligands have been identified by these methods, it has become clear that screening hit lists are plagued by false positives. These nuisance compounds are ultimately found...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151901/ http://dx.doi.org/10.1016/B0-08-045044-X/00053-5 |
_version_ | 1783521355828822016 |
---|---|
author | McGovern, S.L. |
author_facet | McGovern, S.L. |
author_sort | McGovern, S.L. |
collection | PubMed |
description | Computational and experimental high-throughput screening are frequently used to discover new leads for drug design. Although novel ligands have been identified by these methods, it has become clear that screening hit lists are plagued by false positives. These nuisance compounds are ultimately found to be developmental dead-ends and are abandoned, often after considerable effort has been invested in them. Much work over the last decade has been devoted to exploring the origins of false-positive screening hits, and ligand promiscuity has emerged as one such cause. Well-known mechanisms of promiscuity include reactive species and privileged substructures. More recently, it has been found that some nonspecific screening hits form aggregates of 30–1000 nm in diameter. It has been proposed that these aggregate particles are responsible for the promiscuous behavior of many false positives and that aggregate-forming compounds may be widespread among screening hits. This chapter will review the known mechanisms of ligand promiscuity with an emphasis on the recently described model of aggregation. Experimental and computational methods for identifying promiscuous compounds will be described, and some outstanding questions in the field will be considered. |
format | Online Article Text |
id | pubmed-7151901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71519012020-04-13 Promiscuous Ligands McGovern, S.L. Comprehensive Medicinal Chemistry II Article Computational and experimental high-throughput screening are frequently used to discover new leads for drug design. Although novel ligands have been identified by these methods, it has become clear that screening hit lists are plagued by false positives. These nuisance compounds are ultimately found to be developmental dead-ends and are abandoned, often after considerable effort has been invested in them. Much work over the last decade has been devoted to exploring the origins of false-positive screening hits, and ligand promiscuity has emerged as one such cause. Well-known mechanisms of promiscuity include reactive species and privileged substructures. More recently, it has been found that some nonspecific screening hits form aggregates of 30–1000 nm in diameter. It has been proposed that these aggregate particles are responsible for the promiscuous behavior of many false positives and that aggregate-forming compounds may be widespread among screening hits. This chapter will review the known mechanisms of ligand promiscuity with an emphasis on the recently described model of aggregation. Experimental and computational methods for identifying promiscuous compounds will be described, and some outstanding questions in the field will be considered. 2007 2007-04-11 /pmc/articles/PMC7151901/ http://dx.doi.org/10.1016/B0-08-045044-X/00053-5 Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article McGovern, S.L. Promiscuous Ligands |
title | Promiscuous Ligands |
title_full | Promiscuous Ligands |
title_fullStr | Promiscuous Ligands |
title_full_unstemmed | Promiscuous Ligands |
title_short | Promiscuous Ligands |
title_sort | promiscuous ligands |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151901/ http://dx.doi.org/10.1016/B0-08-045044-X/00053-5 |
work_keys_str_mv | AT mcgovernsl promiscuousligands |